An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens

Gabriella Parma, Rosanna Mancari, Gianluca Del Conte, Giovanni Scambia, Angiolo Gadducci, Dagmar Hess, Dionyssios Katsaros, Cristiana Sessa, Andrea Rinaldi, Francesco Bertoni, Andrea Vitali, Carlo Vittorio Catapano, Silvia Marsoni, Helgi Van De Velde, Nicoletta Colombo

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens'. Together they form a unique fingerprint.

Medicine & Life Sciences